Brief: Sellas Life Sciences Announces First Patients Enrolled In 60 Mg Dose Cohort In Phase 2A Clinical Trial Of SLS009 in Acute Myeloid Leukemia
14/12/2023 14:46
Dec 14 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES ANNOUNCES FIRST PATIENTS ENROLLED IN
60 MG
DOSE COHORT IN PHASE 2A CLINICAL TRIAL OF SLS009 IN ACUTE
MYELOID LEUKEMIA
* SELLAS LIFE SCIENCES GROUP INC - EARLY DATA IN 45 MG AND
60 MG
COHORT EXPECTED AROUND YEAR-END 2023
Source text for Eikon: ID:nGNX2qgZ4y
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses